Morgan Stanley Maintains The Chemours(CC.US) With Hold Rating, Maintains Target Price $25
Jefferies Maintains The Chemours(CC.US) With Hold Rating, Raises Target Price to $21
Chemours Analyst Ratings
RBC Capital Maintains The Chemours(CC.US) With Buy Rating, Maintains Target Price $25
RBC Capital Maintains The Chemours(CC.US) With Buy Rating, Cuts Target Price to $25
Chemours Is Maintained at Equal-Weight by Morgan Stanley
Chemours Analyst Ratings
Barclays Maintains The Chemours(CC.US) With Hold Rating, Raises Target Price to $23
Mizuho Securities Maintains The Chemours(CC.US) With Hold Rating
Morgan Stanley Maintains The Chemours(CC.US) With Hold Rating, Maintains Target Price $30
Mizuho Securities Maintains The Chemours(CC.US) With Hold Rating, Cuts Target Price to $22
RBC Capital Maintains The Chemours(CC.US) With Buy Rating, Cuts Target Price to $28
UBS Maintains The Chemours(CC.US) With Buy Rating, Cuts Target Price to $26
UBS Adjusts The Chemours Price Target to $26 From $28, Maintains Buy Rating
Morgan Stanley Maintains The Chemours(CC.US) With Hold Rating, Maintains Target Price $30
BMO Capital Maintains The Chemours(CC.US) With Buy Rating, Raises Target Price to $32
Navigating 7 Analyst Ratings For Chemours
Chemours Is Maintained at Equal-Weight by Barclays
Barclays Maintains The Chemours(CC.US) With Hold Rating, Cuts Target Price to $21
Goldman Sachs Maintains The Chemours(CC.US) With Hold Rating, Cuts Target Price to $23